肺栓塞排除标准对低危急诊患者后续血栓栓塞事件的影响:PROPER随机临床试验
这项在法国14个急诊科进行的交叉整群随机非劣效性试验,纳入临床概率低的可疑肺栓塞患者,比较PERC策略(8项标准均阴性则不做进一步检查排除肺栓塞)与常规策略。主要终点为3个月随访期间新诊断的血栓栓塞事件,非劣效界值为1.5%。结果显示PERC组随访期新发肺栓塞1例(0.1%)vs 对照组0例(差值0.1% [95%CI, -∞至0.8%]),符合非劣效;PERC组CTPA使用率13% vs 23%,急诊停留时间平均缩短36分钟,住院率降低3.3%。结论支持PERC在极低危急诊患者中的安全性。
要点
- 在临床概率极低的可疑肺栓塞急诊患者中,PERC策略(8项均阴性则不做进一步检查)3个月内新发血栓栓塞事件不劣于常规策略。
- PERC组随访期新诊断肺栓塞1例(0.1%)vs 对照组0例,差值0.1%(95%CI, -∞至0.8%),符合预设非劣效界值1.5%。
- PERC策略使CTPA使用率从23%降至13%(差值-10% [95%CI, -13%至-6%],P<.001)。
- PERC策略使急诊停留时间平均缩短36分钟(95%CI, 4至68),住院率降低3.3%(95%CI, 0.1%至6.6%)。
- PERC策略适用于临床概率极低的可疑肺栓塞急诊患者,不适用于临床概率不低者。
适用人群与场景
- 法国14个急诊科中临床概率低(low gestalt clinical probability)的可疑肺栓塞患者,纳入时间2015年8月至2016年9月,随访至2016年12月。
诊断标准与关键阈值
- 肺栓塞排除标准(PERC):8项临床标准,全部阴性时在PERC期排除肺栓塞且不做进一步检查。
处置流程与药物剂量
- PERC期:若8项PERC标准全部阴性,则排除肺栓塞诊断,不做进一步检查。
- 对照期:采用常规策略。
研究设计与关键结果
- 设计:交叉整群随机临床非劣效性试验,14个法国急诊科,1916例患者整群随机(平均年龄44岁,女性980例[51%]),PERC组962例、对照组954例,1749例完成试验。
- 主要终点:3个月随访期间新诊断的血栓栓塞事件;非劣效界值1.5%。
- 初始就诊时诊断肺栓塞:对照组26例(2.7%)vs PERC组14例(1.5%),差值1.3%(95%CI, -0.1%至2.7%),P=.052。
- 随访期新诊断肺栓塞:PERC组1例(0.1%)vs 对照组0例,差值0.1%(95%CI, -∞至0.8%)。
- CTPA使用率:PERC组13% vs 对照组23%,差值-10%(95%CI, -13%至-6%),P<.001。
- 急诊停留时间中位数:PERC组平均缩短36分钟(95%CI, 4至68)。
- 住院率:PERC组降低3.3%(95%CI, 0.1%至6.6%)。
证据类型、等级与局限
- 证据类型:交叉整群随机临床非劣效性试验(PROPER),临床试验注册号NCT02375919。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持PERC用于急诊科就诊的极低危患者的安全性。
- 在临床概率极低的可疑肺栓塞急诊患者中,PERC策略可减少CTPA使用、缩短急诊停留时间并降低住院率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The safety of the pulmonary embolism rule-out criteria (PERC), an 8-item block of clinical criteria aimed at ruling out pulmonary embolism (PE), has not been assessed in a randomized clinical trial.
OBJECTIVE: To prospectively validate the safety of a PERC-based strategy to rule out PE.
DESIGN, SETTING, AND PATIENTS: A crossover cluster-randomized clinical noninferiority trial in 14 emergency departments in France. Patients with a low gestalt clinical probability of PE were included from August 2015 to September 2016, and followed up until December 2016.
INTERVENTIONS: Each center was randomized for the sequence of intervention periods. In the PERC period, the diagnosis of PE was excluded with no further testing if all 8 items of the PERC rule were negative.
MAIN OUTCOMES AND MEASURES: The primary end point was the occurrence of a thromboembolic event during the 3-month follow-up period that was not initially diagnosed. The noninferiority margin was set at 1.5%. Secondary end points included the rate of computed tomographic pulmonary angiography (CTPA), median length of stay in the emergency department, and rate of hospital admission.
RESULTS: Among 1916 patients who were cluster-randomized (mean age 44 years, 980 [51%] women), 962 were assigned to the PERC group and 954 were assigned to the control group. A total of 1749 patients completed the trial. A PE was diagnosed at initial presentation in 26 patients in the control group (2.7%) vs 14 (1.5%) in the PERC group (difference, 1.3% [95% CI, -0.1% to 2.7%]; P = .052). One PE (0.1%) was diagnosed during follow-up in the PERC group vs none in the control group (difference, 0.1% [95% CI, -∞ to 0.8%]). The proportion of patients undergoing CTPA in the PERC group vs control group was 13% vs 23% (difference, -10% [95% CI, -13% to -6%]; P < .001). In the PERC group, rates were significantly reduced for the median length of emergency department stay (mean reduction, 36 minutes [95% CI, 4 to 68]) and hospital admission (difference, 3.3% [95% CI, 0.1% to 6.6%]).
CONCLUSIONS AND RELEVANCE: Among very low-risk patients with suspected PE, randomization to a PERC strategy vs conventional strategy did not result in an inferior rate of thromboembolic events over 3 months. These findings support the safety of PERC for very low-risk patients presenting to the emergency department.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02375919.
参考来源
- Freund Y, Cachanado M, Aubry A, et al. Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial. JAMA. 2018. PMID: 29450523. doi:10.1001/jama.2017.21904
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。